{"id":"W3193354979","doi":"10.3389/fpsyt.2021.701729","title":"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1","year":2021,"lang":"en","type":"article","venue":"Frontiers in Psychiatry","topic":"Autism Spectrum Disorder Research","field":"Neuroscience","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Holland Bloorview Kids Rehabilitation Hospital; University of Toronto","funders":"Horizon 2020; Innovative Medicines Initiative; Medical Research Council; European Federation of Pharmaceutical Industries and Associations; Simons Foundation; European Commission; Autism Speaks","keywords":"Autism; Tolerability; Autism spectrum disorder; Randomized controlled trial; Vineland Adaptive Behavior Scale; Quality of life (healthcare); Psychology; Clinical Global Impression; Clinical psychology; Clinical trial; Placebo; Psychological intervention; Adverse effect; Psychiatry; Medicine; Physical therapy; Internal medicine; Psychotherapist; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007952758,0.004981956,0.006542497,0.001255491,0.001547588,0.001885363,0.003146257,0.004295564,0.02353844],"category_scores_gemma":[0.007091562,0.002093662,0.002087598,0.001405091,0.002475352,0.002420252,0.0009676666,0.006115047,0.004978978],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001568096,"about_ca_system_score_gemma":0.007087681,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000992345,"about_ca_topic_score_gemma":0.002988515,"domain_scores_codex":[0.9964497,0.001854727,0.0002571518,0.0005469612,0.0004478288,0.0004436017],"domain_scores_gemma":[0.9967534,0.0006393402,0.0007595601,0.0003644783,0.0005313017,0.0009520374],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9589561,0.02346151,0.0002659788,0.001538409,0.0004680993,0.00004239591,0.00008063006,0.0004522731,0.003028805,0.0003415197,0.00275357,0.008610798],"study_design_scores_gemma":[0.9710211,0.02677646,0.0003012459,0.00004325962,0.00009801704,0.00001201344,0.000008294875,0.0001892956,0.0001889647,0.0001131141,0.001235237,0.00001306627],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.1868432,0.003554762,0.005293305,0.001366687,0.001663285,0.78624,0.009115669,0.0005995158,0.005323561],"genre_scores_gemma":[0.1227869,0.00227113,0.0104783,0.001816544,0.0006041201,0.8532556,0.003388715,0.00008198465,0.005316661],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.02353844,"threshold_uncertainty_score":0.07874393,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03296690906180837,"score_gpt":0.3582857180665109,"score_spread":0.3253188090047025,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}